FHTX Foghorn Therapeutics
- 5.990
- -0.120-1.96%
- 5.990
- 0.0000.00%
Foghorn Therapeutics News
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53
Even though Foghorn Therapeutics Inc. (NASDAQ:FHTX) has fallen by 31% over the past week , insiders who sold US$72k worth of stock over the past year have had less luck.
Express News | Foghorn Therapeutics Has Appointed Kristian Humer As Chief Financial Officer
Express News | Foghorn Therapeutics Strengthens Financial Leadership With Appointment of Kristian Humer as Chief Financial Officer
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics Price Target Maintained With a $13.00/Share by Wedbush
Foghorn Therapeutics: Buy Rating Affirmed Amidst Promising Pipeline and Strategic Alliances
Express News | HC Wainwright & Co. Reiterates Buy on Foghorn Therapeutics, Maintains $20 Price Target
Foghorn Therapeutics Unveils Cancer Research Breakthroughs
Express News | Foghorn Therapeutics Presents New Preclinical Data On FHD-909,; Says 'FHD-909 Demonstrated Favorable Tolerability and Dose-dependent Single Agent Activity in BRG1 Mutated Cancers Preclinically'
Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs
Foghorn Therapeutics Inc. (Nasdaq: FHTX) today announced new preclinical data for potential first-in-class medicines including FHD-909, a BRM (SMARCA2) selective inhibitor, selective CBP degrader, and selective EP300 degrader programs at the 2024 American Association for Cancer Research (AACR) Annual Meeting. Foghorn management will hold a conference call and webcast today at 5 p.m. ET to review important pipeline updates.
Foghorn Therapeutics to Participate in Needham's 23rd Annual Virtual Healthcare Conference
CAMBRIDGE, Mass., April 05, 2024 (GLOBE NEWSWIRE) -- Foghorn Therapeutics Inc. (NASDAQ:FHTX), a clinical-stage biotechnology company pioneering a new class of medicines that treat serious diseases by correcting
Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction With the 2024 AACR Annual Meeting
Company management will review key pipeline programs, including an update on FHD-286 for AML, new preclinical data for the BRM selective inhibitor FHD-909 and for its selective CBP and EP300 degrader programs Conference
Wall Street Analysts Predict a 124.31% Upside in Foghorn Therapeutics Inc. (FHTX): Here's What You Should Know
Foghorn Therapeutics(FHTX.US) Officer Sells US$72,133.6 in Common Stocks
$Foghorn Therapeutics(FHTX.US)$ Officer Cavalie Fanny sold 11,000 shares of Common Stocks on Mar 11, 2024 at an average price of $6.5576 for a total value of $72,133.6.Source: Announcement What is sta
Foghorn Therapeutics Inc. (NASDAQ:FHTX) Analysts Just Slashed This Year's Estimates
The analysts covering Foghorn Therapeutics Inc. (NASDAQ:FHTX) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for this year. Reven
Express News | Wedbush Reiterates Outperform on Foghorn Therapeutics, Maintains $13 Price Target
Foghorn Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/08/2024 80.56% Wedbush → $13 Reiterates Outperform → Outperform 11/13/2023 -16.67% Morgan Stanley $10 →
Foghorn Therapeutics' FHD-286: A Promising Contender in AML Treatment and Overcoming TKI Resistance
Foghorn Therapeutics: Q4 Earnings Insights
Foghorn Therapeutics (NASDAQ:FHTX) reported its Q4 earnings results on Thursday, March 7, 2024 at 07:00 AM.Here's what investors need to know about the announcement.EarningsFoghorn Therapeutics beat e
Foghorn Therapeutics Inc. (FHTX) Reports Q4 Loss, Tops Revenue Estimates
Analysis
Price Target
No Data
